multiple myeloma
Item
all patients must have a confirmed diagnosis of previously treated, active multiple myeloma, with hypoproliferative/low risk relapse following at least one autologous transplant.
boolean
C0026764 (UMLS CUI [1])
C0194037 (UMLS CUI [2])
age, contraception
Item
patients must be 18 years of age or older. women of childbearing age and fertile men must use a medically acceptable means of birth control while on study and for 6 months thereafter.
boolean
C0001779 (UMLS CUI [1])
C0700589 (UMLS CUI [2])
informed consent
Item
patients must sign an informed consent to participate in this study, and be fully aware of the known teratogenic potential of this drug combination.
boolean
C0021430 (UMLS CUI [1])
performance status
Item
patients must have a swog performance status of 0-2.
boolean
C1518965 (UMLS CUI [1])
renal function
Item
patients must have adequate renal function, as defined by serum creatinine < or = 3.0 mg/dl.
boolean
C0201976 (UMLS CUI [1])
chemotherapy, radiotherapy
Item
patients must be off chemotherapy (including steroids) and local radiotherapy for > or equal 3 weeks prior to entering the study.
boolean
C0392920 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
no other concurrent therapy
Item
no other concurrent therapy for myeloma is permitted while on protocol.
boolean
C0087111 (UMLS CUI [1])
active infection
Item
there must be no evidence of active infection requiring iv antibiotics.
boolean
C0009450 (UMLS CUI [1])